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ttp://dx.doi.org/10.1016/j.ajpath.2014.09.021We investigated whether expression of xylosyltransferase-1 (XT-1), a key enzyme in glycosaminoglycan
biosynthesis, is responsive to disk degeneration and to inhibition by the inﬂammatory cytokines tumor
necrosis factor a and IL-1b in nucleus pulposus (NP) cells. Analysis of human NP tissues showed that
XT-1 expression is unaffected by degeneration severity; XT-1 and Jun, Fos, and Sp1 mRNA were posi-
tively correlated. Cytokines failed to inhibit XT-1 promoter activity and expression. However, cytokines
decreased activity of XT-1 promoters containing deletion and mutation of the e730/e723 bp AP-1
motif, prompting us to investigate the role of AP-1 and Sp1/Sp3 in the regulation of XT-1 in healthy
NP cells. Overexpression and suppression of AP-1 modulated XT-1 promoter activity. Likewise, treatment
with the Sp1 inhibitors WP631 and mithramycin A or cotransfection with the plasmid DN-Sp1 decreased
XT-1 promoter activity. Inhibitors of AP-1 and Sp1 and stable knockdown of Sp1 and Sp3 resulted in
decreased XT-1 expression in NP cells. Genomic chromatin immunoprecipitation analysis showed AP-1
binding to motifs located at e730/e723 bp and e684/e677 bp and Sp1 binding to e227/e217 bp
and e124/e114 bp in XT-1 promoter. These results suggest that XT-1 expression is refractory to the
disease process and to inhibition by inﬂammatory cytokines and that signaling through AP-1, Sp1, and
Sp3 is important in the maintenance of XT-1 levels in NP cells. (Am J Pathol 2015, 185: 485e495;
http://dx.doi.org/10.1016/j.ajpath.2014.09.021)Supported by NIH grants AR055655, AR064733, and AR050087
(M.V.R.) and partly by grant 81101385 from the National Natural Science
Foundation of China (W.Y. and J.Z.).
W.Y. and J.Z. contributed equally to this work.
Disclosures: None declared.Intervertebral disk degeneration is recognized as the most
common cause of low-back pain,1,2 experienced by almost
80% of the population at least once during their lifetime.
The intervertebral disk is composed of gelatinous nucleus
pulposus (NP) enclosed circumferentially by ﬁbrocartilagi-
nous annulus ﬁbrosus (AF); the whole structure is contained
superiorly and inferiorly by a layer of hyaline cartilage, the
endplate. NP and AF are rich in extracellular matrix.
Particularly, NP is abundant in large aggregating pro-
teoglycans, such as aggrecan and versican, that provide the
osmotic properties of the disk critical to withstanding the
high compressive loads applied to the spine. Proteoglycansstigative Pathology.
.are composed of a core protein that is covalently attached by
a variety of glycosaminoglycans (GAGs), such as chon-
droitin sulfate and keratan sulfate. GAGs are of critical
importance in the regulation of NP cell function and organ
development.3e5 GAG chain biosynthesis is initiated by the
formation of a tetrasaccharide (D-GlcA-b1,3-Gal-b1,
Ye et al3-Gal-b1,4-Xyl-Ser) formed by the stepwise addition of
individual sugar residues; the ﬁrst critical step of adding
xylose to serine residue of the core protein is catalyzed by
xylosyltransferase-1 (XYLT1; alias XT-1) and, thus, serves
as an important rate-limiting step in GAG biosynthesis.6e8
A hallmark of intervertebral disk degeneration is the
marked increase in proinﬂammatory cytokines, mainly
tumor necrosis factor a (TNF-a) and IL-1b, which suppress
proteoglycan biosynthesis and promote the expression of
many catabolic enzymes.9e11 The resultant decrease in
proteoglycan matrix and change in matrix composition leads
to gradual loss of tissue water, compromising its biome-
chanical function.12 Although there is some evidence to
suggest that in NP cells the disease process may render the
expression of GlcAT-I, one of the critical enzymes in GAG
biosynthesis, less responsive to niche factors, such as
transforming growth factor b, whether XT-1 expression is
similarly inﬂuenced is not known. Note that altered XT-1
expression levels and, thus, changes in the biosynthesis of
heparan and chondroitin sulfate have been shown to occur
in diseases such as osteoarthritis, dilated cardiomyopathy,
and skin ﬁbrosis.8,13,14 In chondrocytes, XT-1 expression is
suppressed by IL-1b, with Sp1 and Sp3 transcription factors
exerting opposing effects on transcription.15,16 However, in
the case of NP cells, information on transcriptional control
of XT-1 is completely lacking.
We, therefore, sought to investigate the effect of disease
severity and the inﬂammatory cytokines TNF-a and IL-1b on
XT-1 expression and to understand regulation of its expres-
sion in NP cells. These data showed that XT-1 expression in
NP remained unaffected with increasing disease severity in
humans; its expression positively correlated with Jun, Fos,
and Sp1 levels. Unique to NP cells, XT-1 expression was
refractory to the actions of TNF-a and IL-1b,15 and AP-1 and
Sp1/Sp3 positively controlled its transcription.
Materials and Methods
Reagents and Plasmids
XT-1 promoter reporter luciferase constructs (1638/þ1,
797/þ1, AP-1 site: 730/723 mutation in 797/þ1 and
AP1D on 797/þ1) in pGL4.10 vector were a gift from Dr.
Christian Götting (University of Bochum, Bochum, Ger-
many).17 The plasmids were gifts, as follows: A-os/DN-AP1
from Dr. Charles Vinson (NIH, Bethesda, MD) and DN-Sp1
from Dr. Gerald Thiel (University of Saarland Medical
Center, Homburg, Germany). The following were obtained
from Addgene (Cambridge, MA): Jun (catalog #47443)
and pcDNA3-FLAG-Fos (#8966), developed by John
Blenis; pN3-Sp1FL (#24543), pN3-Sp3FL (#24541), and
pN3-control (#24544), by Guntram Suske; and psPAX2
(#12260) and pMD2G (#12259), by Dr. Didier Trono.
Lentiviral shSp1 (clone TRCN0000020448) and shSp3
(clones TRCN0000280368 and TRCN0000280370) were
purchased from Sigma-Aldrich (St. Louis, MO). The486vector pRL-TK (Promega Corp., Madison, WI) containing
the Renilla luciferase gene was used as an internal trans-
fection control.17 The inhibitors WP631, mithramycin A,
and tanshinone IIA were from Sigma-Aldrich. Commer-
cially available antibodies against Sp1, Sp3, and Jun (Cell
Signaling Technology Inc., Danvers, MA); XT-1 (Abcam
Inc., Cambridge, MA); and glyceraldehyde-3-phosphate
dehydrogenase (Novus Biologicals LLC., Littleton, CO)
were used. b-Tubulin antibody was obtained from the
Developmental Studies Hybridoma Bank (University of
Iowa, Iowa City, IA). TNF-a and IL-1b were purchased
from PeproTech (Rocky Hill, NJ). All the PCR primers
were synthesized by Integrated DNA Technologies (Cor-
alville, IA).
Human NP Tissue Collection and Grading
Twenty-ﬁve lumbar and thoracic degenerated disk tissue
samples were obtained from patients undergoing elective
spinal surgical procedures (Pﬁrrmann grade 3: nZ 6, grade 4:
n Z 16, grade 5: n Z 3). Consistent with Thomas Jefferson
University’s Institutional Review Board guidelines, informed
consent for sample collection was obtained from each patient.
The Pﬁrrmann grading scheme was used to assess the disease
state.18
Isolation of NP Cells and Cytokine Treatments
Rat and human NP cells were isolated as described by
Risbud et al.17 For isolation of human NP cells, only visu-
ally healthy, grade 1 or 2 tissues obtained from autopsy or
spinal surgery were used. After isolation, cells were main-
tained in Dulbecco’s modiﬁed Eagle’s medium and 10%
fetal bovine serum supplemented with ampicillin and
streptomycin. To investigate the effect of cytokines and
inhibitors, NP cells were cultured in serum-free medium
overnight and then were treated with 50 ng/mL TNF-a, 10
ng/mL IL-1b, 50 and 100 mmol/L WP631, 100 and 1000
nmol/L mithramycin A, and 50 and 100 mmol/L tanshinone
IIA for 24 hours.
Quantitative Real-Time PCR Analysis
Total RNA was extracted from cells using an RNase-free
DNase I set and a MinElute cleanup kit (both from Qiagen,
Valencia, CA) according to the manufacturer’s in-
structions. Two micrograms of total DNA-free RNA was
used to synthesize cDNA using an EcoDry double-primed
cDNA synthesis kit (Clontech Laboratories, Mountain
View, CA). PCR reactions were set up in duplicate using 1
mL of cDNA with Power SYBR Green master mix
(Applied Biosystems, Foster City, CA) and gene-speciﬁc
forward and reverse PCR primers and were performed
using a StepOnePlus real-time PCR system (Applied
Biosystems). Hypoxanthine phosphoribosyltransferase 1 or
glyceraldehyde 3-phosphate dehydrogenase was used toajp.amjpathol.org - The American Journal of Pathology
Novel Regulation of XT-1 in NP Cellsnormalize the mRNA expression in rat samples. b-Actin
was used to normalize mRNA expression in human sam-
ples. After normalization, expression data were presented
relative to the corresponding control group.
Immunohistochemical Analysis of Disk Tissue
Parafﬁn-embedded sections of rat intervertebral disk tissue
were deparafﬁnized and then rehydrated in graded ethanol.
Antigen retrieval was performed by boiling in 0.01 mol/L
sodium citrate buffer (pH 6.0) at approximately 100C for
15 minutes. After blocking with 10% goat serum for 1 hour,
sections were incubated with antieXT-1 antibody at a
dilution of 1:100 overnight at 4C and then were incubated
with secondary antibody (Alexa Fluor 488econjugated
anti-rabbit; Invitrogen, Carlsbad, CA) for 1 hour at room
temperature. Finally, sections were mounted using DAPI-
containing mounting solution (Vector Laboratories, Bur-
lingame, CA). Cells were imaged using a ﬂuorescence
microscope (Nikon TU200; Nikon Corp, Tokyo, Japan).
Sections incubated with isotype antibody or with secondary
antibody alone served as negative controls.
Protein Extraction and Western Blot Analysis
After treatments, cells were placed on ice immediately and
washed with ice-cold PBS containing 1 complete protease
inhibitor cocktail (Roche Diagnostics Corp., Indianapolis,
IN). The extraction buffer M-PER (Pierce Biotechnology,
Rockford, IL) included 1 protease inhibitor cocktail, 150
mmol/L NaCl, 4 mmol/L NaF, and 20 mmol/L Na3VO4.
Proteins were separated under reducing conditions on 10% to
12% polyacrylamide gels and then were transferred by
electroblotting to polyvinylidene diﬂuoride membranes (Bio-
Rad Laboratories, Hercules, CA). Membranes were incubated
overnight at 4C with the antibodies at a dilution of 1:1000
(XT-1, Sp1, and Sp3) and 1:3000 (glyceraldehyde
3-phosphate dehydrogenase and b-tubulin) after blocking for
1 hour in 5% nonfat dry milk containing Tris-buffered saline
and Tween 20 [50 mmol/L Tris (pH 7.6), 150 mmol/L NaCl,
and 0.1% Tween 20]. Enhanced chemiluminescence reagent
(GE Healthcare, Chalfont St. Giles, UK) was used to detect
the immunolabeling.
Transfections and Dual-Luciferase Reporter Assay
NP cells were seeded in 48-well plates (4  104 cells per
well) with 2% Opti-MEM medium (Invitrogen), and the
following day, cells were cotransfected with 50 to 200 ng of
Jun and/or Fos or DN-AP-1 or 5 to 200 ng of Sp1, Sp3, or
DN-Sp1 plasmids with or without appropriate backbone
vectors and 150 ng of XT-1 reporter and 150 ng of pRL-TK
plasmid. For all transfection, plasmids were premixed with
the transfection reagent Lipofectamine 2000 (Invitrogen).
Forty-eight hours after transfection, the cells were harvested,
and ﬁreﬂy and Renilla luciferase activities were measuredThe American Journal of Pathology - ajp.amjpathol.orgby a Dual-Luciferase reporter assay (Promega Corp.) using
a luminometer (TD-20/20; Turner Designs Inc. Sunnyvale,
CA). In addition, to determine the effect of TNF-a, IL-1b,
and inhibitors, the cells were treated with 50 ng/mL TNF-a
or 10 ng/mL IL-1b, 50 to 100 mmol/L WP631, 100 to 1000
nmol/L mithramycin A, and 50 to 100 mmol/L tanshinone
IIA for 24 hours. All the luciferase assays were performed
in triplicate, and every experiment was repeated at least
three times.
Lentiviral Particle Production and Viral Transduction
HEK 293T cells were seeded in 10-cm plates (3  106 cells
per plate) in Dulbecco’s modiﬁed Eagle’s medium with 10%
heat-inactivated fetal bovine serum. The following day, cells
were transfected with 9 mg of shRNA control or gene-speciﬁc
shRNA plasmids, along with 6 mg of psPAX2 and 3 mg of
pMD2.G. Sixteen hours later, the transfection medium was
replaced with complete Dulbecco’s modiﬁed Eagle’s me-
dium. Media containing viral particles were harvested 48 and
60 hours after transfection and were introduced into human
NP cell cultures (0.5  106 cells per plate) along with 6 mg/
mL Polybrene (Abbott Laboratories, Abbott Park, IL). The
medium containing viral particles was removed after 24
hours and replaced with Dulbecco’s modiﬁed Eagle’s me-
dium with 10% fetal bovine serum and antibiotics. Five days
later, cells were harvested for protein or RNA extraction.
Chromatin Immunoprecipitation
Chromatin immunoprecipitation (ChIP) assay was performed
using a ChIP-IT high-sensitivity kit (Active Motif, Carlsbad,
CA). Brieﬂy, human NP cells were cultured in 100 mm until
80% conﬂuence. Cells were cross-linked and lyzed, and
chromatin was sheared by sonication, and input DNA was
generated by treating aliquots with RNase, proteinase K, and
heat, followed by ethanol precipitation. DNA complexes were
immunoprecipitated by incubation with rabbit polyclonal
anti-Jun or anti-Sp1 antibodies or preimmune IgG overnight
as negative control at 4C followed by binding to protein
Geagarose beads for 3 hours at 4C. Cross-links were
reversed by treatment with proteinase K and heat for 2.5
hours, and DNA was puriﬁed using DNA puriﬁcation elution
buffer (Active Motif). Real-time PCR analysis was performed
using a ChIP-IT quantitative PCR analysis kit (Active Motif)
and the following primer pairs (forward and reverse) for pu-
tative AP-1 and Sp1 sites in the XT-1 promoter: 730/723
bp AP-1: 50-TTGCCGCTATACCACTT-30 and 50-GTGCC-
AACGATGTACTAAG-30; 684/677 bp AP-1: 50-CAC-
TTAGTACATCGTTGGC-30 and 50-GCTTTGGGTGAGTT-
TCTG-30; and 228/224 bp and 124/114 bp Sp1:
50-CCTTCCTTTCCCTCCTCCTTT-30 and 50-CCGCCAC-
CATCTTCGGA-30. The negative control primers and
standard curve primers used were provided with the kit.
Real-time PCR was performed using Power SYBR Green
PCR master mix (Applied Biosystems). The CT values487
Figure 1 Relationship of xylosyltransferase-1 (XT-1) mRNA expression to severity of human disk disease and Jun, Fos, and Sp1 levels. AeD: mRNA expression
analysis of XT-1 (A), Jun (B), Fos (C), and Sp1 (D) from nucleus pulposus (NP) tissues with different Pﬁrrmann grades (G3 to G5). No signiﬁcant differences were
observed in any of these genes between different grade samples (NZ 25; G3: nZ 6, G4: nZ 16, G5: nZ 3). The data are represented as box and whisker plots. Open
circles denote outliers that fall outside of 1.5 times the upper or lower quartile range. Each box represents the 75the25th percentile of values, the line inside each
box represents the median value separating the upper and lower quartiles, and whiskers show the maximum and minimum values excluding outliers in each set. EeG:
A positive correlation in mRNA levels between Jun and XT-1 (rZ 0.858, P< 0.0001) (E), Fos and XT-1 (rZ 0.848, P< 0.0001) (F), and Sp1 and XT-1 (rZ 0.884,
P< 0.0001) (G) was observed. H: Section of the rat NP tissue treated with XT-1 antibody showed prominent cytoplasmic localization of protein in NP cells. DAPI was
used to stain cell nuclei. I and J:Western blot (I) and corresponding densitometric (J) analyses of XT-1 expression in rat NP and annulus ﬁbrosus (AF) tissues showed
prominent expression in NP compared with AF tissue. Data represent means  SEM of three independent experiments performed in triplicate. *P < 0.05. GAPDH,
glyceraldehyde-3-phosphate dehydrogenase.
Ye et alwere recorded, and the data were normalized based on
primer efﬁciency, input DNA CT values, amount of
chromatin, and resuspension volume, based on the man-
ufacturer’s recommendations.Statistical Analysis
All the experiments were performed independently at least
three times. Data are presented as means  SEM. Differ-
ences between groups were analyzed by one-way analysis of
variance and Student’s t-test. RT-PCR expression data of
human tissues was found to be nonparametric; therefore, the
Kruskal-Wallis test was used to determine signiﬁcance
between 2DCT values between study groups. In addition,
the Spearman rank correlation was deployed to determine488correlations between gene expressions for different targets.
P < 0.05 was considered statistically signiﬁcant.Results
XT-1 mRNA Expression Is Unaffected by Severity of
Disk Disease and Shows Correlation with Jun, Fos, and
Sp1 in Human NP Tissues
To investigate the relationship between XT-1 expression
and severity of disk degeneration, we measured mRNA
expression using 25 human NP tissues with increasing
grades of disease. The results show that there was no
signiﬁcant difference in expression levels of XT-1 (Figure 1A)
between NP tissues with early (grade 3) and late (grades 4ajp.amjpathol.org - The American Journal of Pathology
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Figure 2 Xylosyltransferase-1 (XT-1) expression in nucleus pulposus (NP) cells is refractory to inhibition by tumor necrosis factor a (TNF-a) and IL-1b
and is maintained through AP-1 signaling. A: Schematic of 1638/þ1 bp and 797/þ1 bp human XT-1 promoter constructs showing AP-1 and Sp1 binding
sites used for the studies. B and C: Rat NP cells transfected with both wild-type XT-1 promoter constructs showed no change in promoter activity in
response to TNF-a and IL-1b treatment (B). NP cells transfected with the 797/þ1 bp construct harboring either mutation (B) or deletion (C) of
the 730/723 bp AP-1 site showed a decrease in activity in response to cytokines. D and E: NP cells were cotransfected with DN-AP-1 and the 797/þ1
bp XT-1 promoter construct and were treated with either TNF-a (D) or IL-1b (E). The XT-1 promoter showed no change in activity in response to cytokines
alone; however, activity declined after cytokine treatment in the presence of DN-AP-1. FeH: Quantitative PCR (F) and Western blot (G) and corresponding
densitometric (H) analyses of NP cells treated with TNF-a or IL-1b until 24 hours. Cytokine treatment showed no signiﬁcant change in XT-1 mRNA (F) and
protein (G and H) levels. Data represent means  SEM of three independent experiments performed in triplicate. *P < 0.05. Ctr, control; luc, luciferase; WT,
wild type; WT-FL, wild type-full length.
Novel Regulation of XT-1 in NP Cellsand 5) stages of degeneration. In addition, we measured
mRNA expression of Jun, Fos, and Sp1, transcription factors
that have been associated with XT-1 expression in other cell
types.7,13 Similar to XT-1, expression of Jun (Figure 1B), Fos
(Figure 1C), and Sp1 (Figure 1D) was similar between tissues
with different grades. Expression of Jun and XT-1 (Figure 1E)
(r Z 0.858, P < 0.0001), Fos and XT-1 (Figure 1F)
(r Z 0.848, P < 0.0001), and Sp1 and XT-1 (Figure 1G)
(rZ 0.884, P < 0.0001) signiﬁcantly correlated with each
other.
To investigate the expression of XT-1 in healthy disk
tissues, sagittal sections of rat disk were stained with an
antibody to XT-1 to examine the expression pattern. XT-1
was prominently expressed in NP cells (Figure 1H). InThe American Journal of Pathology - ajp.amjpathol.orgaddition, XT-1 expression in discal tissues of mature rat was
studied using Western blot analysis. Results show that the
expression level of XT-1 protein in NP tissue is signiﬁcantly
higher than that in the AF (Figure 1, I and J).
XT-1 Expression Is Refractory to Inhibition by TNF-a
and IL-1b and Is Maintained by AP-1
TNF-a and IL-1b are the key inﬂammatory cytokines that
promote intervertebral disk degeneration, and IL-1b is shown
to suppress XT-1 levels in chondrocytes.9e11,15 To delineate
the effect of these cytokines on XT-1 expression, we ﬁrst
measured the activity of two promoter fragments, a larger
1638/þ1 bp and a smaller 797/þ1 bp (Figure 2A) in rat489
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Figure 3 AP-1 signaling controls basal XT-1 promoter activity in nucleus pulposus (NP) cells. A: Effect of Fos overexpression on XT-1-wild-type (WT)
promoter activity. Note the dose-dependent increase in XT-1 reporter activity with increasing concentrations of Fos. B: Jun overexpression induced XT-1
promoter activity in a dose-dependent manner. C: Cotransfection of Jun and Fos signiﬁcantly increased the XT-1 promoter activity compared with their in-
dividual addition. D: DN-AP-1 diminished the activity of XT-1 promoter in a dose-dependent manner. E: DN-AP-1 has no effect on XT-1 reporter activity
harboring a mutation in 730/723 bp AP-1 motif. F: DN-AP-1 suppresses activity of the XT-1 promoter with deletion of 730/723 bp AP-1 motif. G:
Genomic chromatin immunoprecipitation analysis to detect AP-1 binding to XT-1 promoter in human NP cells. Pull down using Jun antibody clearly showed
signiﬁcant enrichment of binding to AP-1 motifs at 730/723 bp and 684/677 bp over IgG alone. Negative primers (Neg) showed little or no
ampliﬁcation for experimental and IgG control samples. Values shown are means  SEM of three independent experiments. *P < 0.05.
Ye et alNP cells after treatment with TNF-a and IL-1b. There are two
conserved, functional AP-1 binding sites at 730/723 bp
and 684/677 bp and two conserved, functional Sp1
binding sites at 227/217 bp and 124/114 bp within
797 bp of the human XT-1 promoter (Figure 2A).16 The
activity of both the fragments was unresponsive to cytokine
treatment (Figure 2B). Next, to determine whether AP-1
maintained XT-1 promoter activity in the presence of cyto-
kines, we used reporters harboring AP-1 site mutation or
deletion. Results show that unlike wild-type reporters, TNF-a
and IL-1b signiﬁcantly decreased the activity of these AP-
1edeﬁcient constructs (Figure 2, B and C). To conﬁrm the
contribution of AP-1 to sustain XT-1 transcription, we
cotransfected rat NP cells with DN-AP-1 plasmid and
measured the activity of wild-type XT-1 reporter with or
without cytokines. Again, when AP-1 function was blocked,
TNF-a (Figure 2D) or IL-1b (Figure 2E) signiﬁcantly sup-
pressed the promoter activity. Furthermore, in agreement with
our promoter studies and in contrast to a previous report of
chondrocytes,15 the cytokines did not affect XT-1 mRNA
(Figure 2F). Western blot and subsequent densitometric ana-
lyses also showed a lack of suppressive effect of cytokines on
XT-1 protein levels (Figure 2, G and H).
AP-1 Signaling Pathway Controls Basal XT-1
Transcription in NP Cells
To determine whether AP-1 controls XT-1 promoter activity,
we performed classical gain- and loss-of-function experi-
ments by cotransfecting 797/þ1 bp XT-1 promoter490construct with Jun and/or Fos and DN-AP1 plasmids. Results
show that increasing concentrations of Fos (Figure 3A) as
well as Jun (Figure 3B) robustly enhanced promoter activity
in a dose-dependent manner. Moreover, co-expression of Jun
and Fos produced much stronger induction of promoter ac-
tivity (Figure 3C). On the other hand, cotransfection with DN-
AP-1 resulted in strong suppression of promoter activity; even
at a dose of 50 ng, a suppressive effect was evident
(Figure 3D). However, DN-AP-1 evidenced no effect on XT-1
promoter harboring mutation in the AP-1 motif located at
730/723 bp (Figure 3E). DN-AP-1 suppressed the activity
of XT-1 promoter with deletion of the AP1 binding site at
730/723 bp (Figure 3F). These results indicated that the
AP-1 (Jun/Fos) controls human XT-1 promoter function. To
delineate whether AP-1 binds to the XT-1 gene promoter, we
assessed its binding to cognate AP-1 motifs by ChIP analysis.
There was approximately 13-fold enrichment in binding of
Jun to a site located at 684/677 bp compared with the IgG
control, whereas fourfold enrichment of Jun binding was
detected at a motif located at730/723 bp of the human XT-
1 promoter (Figure 3G). As expected, negative control primers
showed almost undetectable ampliﬁcation.Sp1/Sp3 Transcription Factor Controls XT-1 Promoter
Activity in NP Cells
To further examine whether the Sp1 and Sp3 transcription
factors control XT-1 promoter activity, we measured the
activity of 797/þ1 XT-1 promoter ﬁrst in the presence ofajp.amjpathol.org - The American Journal of Pathology
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Figure 4 Sp1 controls XT-1 promoter activity in nucleus pulposus (NP) cells. A and B: Effect of Sp1 inhibitors WP631 (A) and mithramycin A (Mith A) (B) on
XT-1 promoter activity in rat NP cells. Both inhibitors signiﬁcantly suppressed basal XT-1 promoter activity. C: Transfection of rat NP cells with increasing doses
of DN-Sp1 suppressed XT-1 promoter. D and E: Overexpression of Sp1 (D) or Sp3 (E) did not inﬂuence the activity of XT-1 promoter in NP cells. F: Genomic
chromatin immunoprecipitation analysis to detect Sp1 binding to XT-1 promoter in human NP cells. Pull down using Sp1 antibody showed signiﬁcant
enrichment of binding to Sp1 motifs at 227/217 bp and 124/114 bp over IgG alone. Negative primers (Neg) showed little or no ampliﬁcation for
experimental and IgG control samples. Values shown are means  SEM of three independent experiments. *P < 0.05. DMSO, dimethyl sulfoxide.
Novel Regulation of XT-1 in NP Cellsthe Sp1 inhibitor WP631 or mithramycin A, which through
binding to GC-rich DNA motifs displaces bound Sp1 from
promoters and serves as its transcriptional inhibitor. The
results showed that WP631 (Figure 4A) and mithramycin A
(Figure 4B) signiﬁcantly suppressed the activity of XT-1
promoter in rat NP cells. In parallel, we cotransfected NP
cells with DN-Sp1 to assess the effect of lowered Sp1
activity on XT-1 promoter. It was evident that the addition of
DN-Sp1 signiﬁcantly reduced the basal activity of XT-1
promoter (Figure 4C). To complement these loss-of-function
experiments, we performed gain-of-function assays by
cotransfecting XT-1 promoter along with full-length Sp1 and
Sp3. The results showed that exogenously overexpressed Sp1
(Figure 4D) or Sp3 (Figure 4E) did not increase the activity
of XT-1 promoter in NP cells. To determine whether Sp1
binds to its cognate sites in XT-1 promoter, we performed
ChIP analysis using human NP cells. When Sp1 antibody
was used for the chromatin pull down, approximately eight-
fold enrichment in amplicon encompassing both 227/217
bp and 124/114 bp binding sites was detected over the
IgG control (Figure 4F).
Treatment with AP-1 and Sp1 Inhibitors Suppresses
XT-1 Expression in NP Cells
After the promoter studies, to investigate the effects of AP-1
inhibition on XT-1 expression we treated rat NP cells with
tanshinone IIA, an AP-1 inhibitor, for 24 hours and
measured mRNA levels. Treatment with 50 and 100 mmol/L
tanshinone IIA decreased XT-1 mRNA expression to 72%The American Journal of Pathology - ajp.amjpathol.organd 45%, respectively, of untreated control (Figure 5A). To
further test the inhibitory role of Sp1 inhibition on the XT-1
mRNA expression, NP cells were treated with WP631 or
mithramycin A for 24 hours. The results show that treatment
with WP631 resulted in a dose-dependent decrease in XT-1
mRNA expression (Figure 5B). Similarly, with increasing
concentrations of mithramycin A, XT-1 mRNA levels were
decreased to 65% and 54%, respectively (Figure 5C). To
determine whether the inhibition of AP-1 and Sp1 affects
XT-1 protein levels, we performed Western blot analysis
after the treatment of NP cells with 100 mmol/L WP631, 1
mmol/L mithramycin A, or 100 mmol/L tanshinone IIA for
24 hours. The results show that compared with nontreated
cells, the inhibitor treatment resulted in a signiﬁcant
decrease in XT-1 protein levels (Figure 5, D and E).
Stable Silencing of Sp1 and Sp3 Decreases XT-1
Expression
To further delineate the novel complementary role of Sp1
and Sp3 in controlling XT-1 expression in NP cells, we
performed Sp1 and Sp3 loss-of-function studies using len-
tiviral delivery of gene-targeting shRNAs. As expected, in
human NP cells transduced with shSp1 or shSp3#2, the
mRNA expression of Sp1 or Sp3 signiﬁcantly decreased by
approximately 88% and 86%, respectively, compared with
cells transduced with control shRNA. One of two shRNAs
targeting Sp3 (shSp3#1) did not result in the suppression of
Sp3 levels. In Sp1- and Sp3-supressed cells, XT-1 mRNA
expression is markedly reduced by approximately 82%491
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Ye et al(Figure 6A) and 70% (Figure 6B), respectively, of the
control cells. Furthermore, we investigated the expression of
XT-1 protein in the Sp1- and Sp3-silenced cells using
Western blot analysis. Compared with the NP cells trans-
duced with control shRNA, shSp1 or shSp3 resulted in a
signiﬁcant decrease in Sp1 (Figure 6, C and D) or Sp3
(Figure 6, E and F) protein. Consistent with the changes in
mRNA, XT-1 protein expression in Sp1- (Figure 6C) or
Sp3- (Figure 6E) silenced cells was decreased by approxi-
mately 70% (Figure 6D) and 66% (Figure 6F), respectively,
of the control cells.Discussion
The experiments described in this investigation demonstrate
for the ﬁrst time that the expression of XT-1, a key enzyme
that catalyzes the initial step in GAG biosynthesis, is
refractory to actions of the inﬂammatory cytokines TNF-a
and IL-1b and that XT-1 expression is similar between the
early and late stages of the degenerative process. A second
major observation was that Jun/AP-1 and complementary
actions of members of the Sp transcription factor family,
Sp1 and Sp3, are essential for the maintenance of XT-1
expression in NP cells through interaction with respective
cognate binding sites in XT-1 promoter. Jun, Fos, and Sp1
expression positively correlated with XT-1 expression in492human NP tissues. Taken together, these ﬁndings, for the
ﬁrst time, present novel insights into the expression and
regulation of XT-1 in the intervertebral disk and highlight
clear differences compared with other cartilaginous tissues.
Biomechanical function of the intervertebral disk is
directly related to its ability to bind and retain water in the
aggrecan-rich matrix of the NP; therefore, understanding the
mechanisms that control GAG synthesis in NP cells is of
paramount importance. Note that increased proteoglycan
catabolism and reduced overall aggrecan and GAG content
are hallmarks of intervertebral disk degeneration.19 Because
XT-1 represents the ﬁrst and most important rate-limiting
step in GAG biosynthesis, we investigated whether the
expression was responsive to the disease process. To our
surprise, and in contrast to osteoarthritis, the lack of dif-
ference in XT-1 levels in NP tissues with early and late
grades of degeneration suggested that expression was
refractory to disease progression.13 Because AP1 and Sp1/
Sp3 have been shown to control XT-1 expression in other
cell types,8,15 we also measured their expression levels in
human NP tissues. AP-1 components Fos and Jun are re-
ported to be expressed in extrusions, sequesters, and pro-
trusions of human intervertebral disks.20 In agreement, the
present studies conﬁrmed that Jun, Fos, and Sp1 are
expressed in degenerate human NP tissues. Although no
apparent difference in expression of these transcription
factors was observed, a strong positive correlation betweenajp.amjpathol.org - The American Journal of Pathology
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Figure 6 Stable silencing of Sp1 or Sp3
using lentivirally delivered shRNAs decreases
xylosyltransferase-1 (XT-1) expression in human
nucleus pulposus (NP) cells. A and B: Real-time
PCR analysis of human NP cells transfected with
LV-sh-control (LV-shC) or LV-shSp1 (A) or LV-
shSp3#2 (B). XT-1 mRNA expression was signiﬁ-
cantly suppressed by LV-shSp1 and LV-shSp3#2
compared with cells transduced with control
lentivirus (LV-shC). Strong suppression in Sp1 and
Sp3 mRNA expression was observed with corre-
sponding gene-targeting shRNAs. CeF: Western
blot (C and E) and corresponding densitometric (D
and F) analyses of NP cells transduced with LV-shC
or LV-shSp1 (C and D) or LV-shSp3 (E and F). XT-1
expression levels were suppressed by LV-shSp1 and
LV-shSp3#2 compared with cells transduced with
control shRNA. Targeting sequence shSp3#1 did
not result in the suppression of Sp3 levels. As
expected, transduction of cells with shSp1 or
shSp3#2 showed a corresponding decrease in Sp1
or Sp3 protein levels. Data represent means  SEM
of three independent experiments performed in
triplicate. *P < 0.05.
Novel Regulation of XT-1 in NP CellsXT-1 and Jun or Fos as well as Sp1 suggested that they are
likely involved in maintaining a steady state of XT-1
expression in NP cells during disease. Moreover, robust
expression of XT-1 in healthy NP tissue compared with AF
supported the hypothesis that GAG biosynthesis is likely to
be more active in mature native NP tissue than in AF.
Tissue analysis raised an important question: How do in-
ﬂammatory cytokines affect XT-1 expression in NP cells?
TNF-a and IL-1b are the key inﬂammatory cytokines asso-
ciated with degenerative disk disease; our recent results also
showed that they promote matrix degradation through the
expression and activation of many catabolic enzymes.9,11,21
Moreover, IL-1b is shown to affect GAG synthesis by
down-regulating the expression of GlcAT-I and XT-1 in
chondrocytes,15,22 wherein XT-1 suppression is mediated by
displacement of Sp1 and enhanced recruitment of Sp3 to the
gene promoter.15 We, therefore, investigated whether such
repression of XT-1 by cytokines is observed in NP cells.
These results revealed that in NP cells, XT-1 promoter
activity and its mRNA and protein levels were unaffected by
TNF-a or IL-1b. This may be explained by a previousThe American Journal of Pathology - ajp.amjpathol.orgobservation that Sp1 DNA binding is unaffected by TNF-a in
NP cells.23 Moreover, decreased activity of promoter with
AP-1 e730/e723 bp binding site mutation or deletion by
TNF-a or IL-1b suggested that AP-1 was responsible for
sustaining transcription in the presence of cytokines.
AP-1 transcription factor has been shown to control the
expression of GAG biosynthetic enzymes and matricellular
proteins important for intervertebral disk function.24,25 In
XT-1 promoter, several binding sites of AP-1 that are active
in transcription have been reported.1,15,16 We, therefore,
hypothesized that transcription factor AP-1 may also be
involved in regulating basal XT-1 expression even in
healthy NP cells. Gain- and loss-of-function studies using
XT-1 promoter clearly indicated that Jun and Fos activated
the transcription. Site-directed mutagenesis suggested that
AP-1 binding to motif at 730/723 bp is the preferential
site for maintenance of the promoter activity. However,
unlike the mutant, deletion of the 730/723 bp AP-1
site resulted in promoter gaining responsiveness to sup-
pression by DN-AP-1, indicating that Jun recruited at 684/
677 bp could control transcription perhaps owing to better493
Ye et alaccessibility to the transcriptional machinery. Results of
genomic ChIP analysis that showed enrichment of Jun
binding to both AP-1 motifs in NP cells provided further
support to the functional studies and the hypothesis that
AP-1 recruitment to XT-1 promoter controls its basal tran-
scription. Decreased levels of mRNA and protein in the
presence of AP-1 inhibitor tanshinone IIA conﬁrmed that
AP-1 maintains basal expression of XT-1 in NP cells.
Sp1 and Sp3, members of the Sp protein family, have a
similar structure and bind to the same cognate Sp1 binding
sites. However, their DNA-binding properties and regulatory
functions are different.26 In many cell types, Sp1 and Sp3 exert
opposing effects on gene transcription, and the ratio of these
two proteins determines the expression level of the target
gene, as demonstrated for collagen II transcription in
chondrocytes.27e29 In the intervertebral disk, recent results
have shown that transcription factors AP-1 and Sp1 are
involved in controlling the basal expression of GlcAT-I, an
enzyme that controls GAG synthesis.25 Relevant to this dis-
cussion, in SW1353 cells, Sp1 knockdown had no detectable
effect on the XT-1 mRNA levels, whereas knockdown of Sp3
led to a highly signiﬁcant reduction.16 Mutation analysis of
Sp1 binding sites of XT-1 promoter in primary chondrocytes
showed that disruption of the Sp1 e227/e217 bp core
sequence resulted in 80% loss of XT-1 promoter activity,
whereas mutation of Sp1 e124/e114 bp stimulated XT-1
promoter activity by 66%, suggesting that Sp1e124/e114 bp
may be essential for repression of the XT-1 gene expression.15
To understand the role of Sp1 and Sp3 in the regulation ofXT-1
expression in NP cells, we performed loss- and gain-of-
function studies. The studies conclusively showed that sup-
pression of Sp1 transcriptional activity using either a
dominant-negative approach or inhibitors resulted in decreased
XT-1 promoter activity. In contrast to AP-1, apparent unre-
sponsiveness of XT-1 promoter activity to overexpression of
Sp1 and Sp3 may suggest saturating levels of Sp1/Sp3 present
in NP cells. These functional studies were further supported by
a genomic ChIP analysis that demonstrated enriched binding
of Sp1 to theXT-1 promoter fragment that contained the227/
217 bp and 124/114 bp binding sites. Unlike the previ-
ously suggested differential role of Sp1 and Sp3 in XT-1
transcription and other matrix genes,15,27,28 a robust decrease
in XT-1 mRNA and protein after inhibitor treatment and stable
silencing of Sp1 or Sp3 supported the positive contribution of
these factors in XT-1 expression in NP cells. Taken together,
the results of this study clearly show that AP-1, Sp1, and Sp3
are critical for the maintenance of XT-1 expression under
physiologic and pathophysiologic conditions in NP cells.References
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